Orazol

Omeprazole

Method of action: Antacid, Antiulcer, Drugs For Acid Related Disorders, Inhibiting H +, K + -Atp-Ase, Proton Pump Inhibitor

Treatment option: Duodenal Ulcer, Heartburn, Reflux, Esophageal Reflux, Reflux Esophagitis, Zollinger-Ellison Syndrome, Helicobacter Pylori, Esophagitis, Stomach Ulcer, Peptic Ulcer

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Orazol

Property	Description
Active ingredient	Omeprazole (INN)
Form	Enteric-coated capsule or tablet
Pharmacological class	Proton Pump Inhibitor (PPI)
General purpose	Gastric acid secretion reduction
Origin	Synthetic (Substituted Benzimidazole)

What Type of Medicine is Orazol?

Orazol is a pharmaceutical preparation containing the active substance Omeprazole, which is classified as a potent Proton Pump Inhibitor (PPI) and belongs to the broader group of Antiulcer Agents. This is a synthetic, single-ingredient compound derived from the substituted benzimidazole chemical group. The preparation is typically supplied as prescription-only (Rx), distinguishing it from some lower-dose, over-the-counter forms of Omeprazole.

The primary function of this classification is to provide reliable, long-term control over acid levels within the stomach, a characteristic clinically recognized for its superior acid-suppressing capability compared to earlier generations of acid reducers.

Orazol's Composition and Specialized Form

The active ingredient in Orazol is Omeprazole, delivered for oral administration, typically as a specialized enteric-coated or delayed-release capsule or tablet. This formulation is essential because the Omeprazole compound is chemically vulnerable and would be rapidly destroyed by the highly acidic conditions inside the stomach.

To ensure the drug remains fully effective, the preparation uses pharmaceutical excipients to create a protective barrier that bypasses the acidic environment. This design allows the Omeprazole to dissolve only when it reaches the less acidic environment of the small intestine, from which it is then absorbed into the bloodstream. The specialized coating system is critical to the drug's oral bioavailability.

General Purpose: How Orazol Helps the Body

The fundamental purpose of Orazol is to achieve a significant and sustained reduction of gastric acid secretion by directly deactivating the acid-producing machinery. Omeprazole achieves its overall goal by targeting and irreversibly inhibiting the final stage of acid output within the gastric parietal cells.

This consistent lowering of acid production provides a therapeutic effect by mitigating the corrosive effects of excessive acidity. By profoundly reducing both the continuous basal acid output and the meal-induced stimulated acid output, the drug creates a less hostile environment, which is its core benefit in addressing symptoms related to acid excess.

Regulatory References

What side effects are possible with Orazol?

Possible Side Effects and Safety Information

The safety profile for the active substance in Orazol, Omeprazole, is formally classified by regulatory agencies based on the observed frequency and the affected System Organ Class (SOC). The majority of reactions are generally categorized as common and often occur at the initiation of treatment.

Adverse Reaction Classifications

The following summary reflects adverse reactions documented in official prescribing information:

Common Reactions (Affecting 1 to 10 users in 100): Effects primarily involving the Gastrointestinal System (e.g., abdominal pain, constipation, diarrhoea, flatulence, nausea, vomiting) and the Nervous System (e.g., headache).
Uncommon Reactions (Affecting 1 to 10 users in 1,000): These include effects such as insomnia, dizziness, increased liver enzymes, rash, and peripheral oedema.
Rare/Very Rare Reactions: These reactions affect fewer users but include clinically significant events, such as certain blood disorders (e.g., leukopenia, agranulocytosis), severe hypersensitivity reactions (e.g., anaphylaxis), hepatic failure, and severe skin conditions (e.g., Stevens-Johnson syndrome).

Important Safety Patterns

Official regulatory documents highlight specific safety patterns tied to the duration of exposure:

Long-Term Exposure: Prolonged or high-dose therapy is associated with documented risks, including hypomagnesaemia (low magnesium levels) and an increased risk of bone fracture of the hip, wrist, or spine. This risk is particularly noted in older adults.
Safety Constraints: The use of Omeprazole is contraindicated in patients with known hypersensitivity to the active substance or related substituted benzimidazoles. Caution is also specified for patients with hepatic impairment, as the drug is metabolized in the liver.

Overdose and Emergency Response

Overdose and When to Seek Help

The information below outlines the officially documented presentations and required actions for Orazol overdose, based strictly on government regulatory labeling.

Property	Official Regulatory Statement
Documented Overdose Manifestations	Symptoms observed in association with overdose are generally described as transient and non-serious. Documented effects may include gastrointestinal disturbances such as nausea, vomiting, abdominal pain, and diarrhea. Central nervous system effects such as headache, confusion, and drowsiness have also been noted [1.4, 2.1].
Management Principle	Treatment for suspected overdose is strictly symptomatic and supportive, as no specific antidote is known according to regulatory documentation. Careful patient monitoring is required during the post-overdose period [3.5].
When Urgent Medical Help is Required	Seek immediate medical attention or call a Poison Help line for any suspected overdose [2.5]. Emergency services must be called immediately if the affected individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened [2.5].
Population Note	Specific consideration for hepatic impairment is noted in labeling, suggesting a potential for higher systemic drug exposure in an overdose scenario for this population [2.1].

Regulatory documents define the overdose profile by listing specific, typically mild and temporary, clinical signs and confirming the lack of a known antidote. This information dictates that the required action is to seek immediate medical attention for evaluation, with clear instructions to contact emergency services for severe, life-threatening symptoms.

Therapeutic Uses of Orazol

What Orazol Treats: Main Uses and Benefits

Similar therapeutic agents are generally considered relevant when short-term symptomatic assistance is needed. Orazol is relevant in this context. It is commonly used in situations involving certain distressing symptoms, particularly in clinical settings that involve acute or unstable symptom patterns.

Orazol is applied across domains where additional symptomatic support is needed. It helps address symptom clusters that may become intense or disruptive, such as those associated with episodic or fluctuating manifestations. This medicine contributes to improved comfort during periods where symptoms are more noticeable and may support general well-being during symptomatic phases.

Quick Fact: Relevant for Symptomatic Discomfort

“Orazol is applied in scenarios where additional management of discomfort is required, and supports patients during difficult episodes by easing distress.”

Eligibility and Restrictions for Use

This section outlines the official eligibility and non-eligibility rules for Orazol (Omeprazole) as documented in government regulatory sources, strictly defining which populations are permitted or restricted from using the medicine. It does not provide medical advice or instructions on dosing.

Populations Who Must NOT Use Orazol (Contraindications)

The medicine is absolutely prohibited for use in patients with:

A known hypersensitivity to the active ingredient, Omeprazole, any substituted benzimidazoles (the drug class), or any component of the formulation.
Concomitant therapy with certain antiretroviral agents, specifically Nelfinavir or Rilpivirine-containing products.
Rare hereditary problems related to excipients, such as fructose intolerance, glucose-galactose malabsorption, or sucrase-isomaltase insufficiency.

Eligibility Rules for Specific Populations

Population Category	Official Regulatory Status
Pediatric Patients	Safety is not established in children younger than 1 month of age. Use is established and permitted in children 1 month of age and older.
Geriatric Patients	Use is permitted; dose adjustment is not generally needed.
Hepatic Impairment	Restricted use is required. Caution is advised, and some regulators recommend dose reduction or avoidance of maintenance therapy in patients with severe hepatic impairment.
Renal Impairment	Use is permitted, and dose adjustment is not required according to regulatory documents.
Pregnancy	Use is generally considered acceptable or can be used if necessary based on available epidemiological data.
Lactation	Use is generally considered acceptable, as limited data suggests maternal doses are not likely to cause adverse effects in breastfed infants.

What should I know about interactions with other medicines?

Orazol's active ingredient is miconazole, an azole antifungal agent. Although the systemic absorption of miconazole from the buccal tablet is minimal, a potential for drug interactions exists due to miconazole being a known inhibitor of certain Cytochrome P450 (CYP) enzymes, particularly CYP2C9 and CYP3A4. This means Orazol may affect the way other medicines metabolized by these enzymes are processed by the body.

Clinically Significant Interaction

The most important documented interaction is with Warfarin, a medicine used to prevent blood clots. Concomitant use of miconazole with Warfarin has resulted in an enhancement of the anticoagulant effect, which increases the risk of bleeding and bruising. This effect is attributed to miconazole's inhibition of CYP2C9, the enzyme responsible for Warfarin's metabolism.

Procedural Interaction Constraint

If Orazol is used alongside Warfarin or other anticoagulants, frequent monitoring of blood clotting indicators, such as Prothrombin Time (PT) and International Normalized Ratio (INR), is required. Healthcare providers should closely watch for signs of bleeding in these patients. The potential for interaction also extends to other drugs metabolized by CYP2C9 or CYP3A4, including certain oral hypoglycemics, phenytoin, or ergot derivatives, even with the minimal systemic exposure from the buccal route.

Mechanism of Action

Irreversible Blockade of the Gastric Proton Pump

Orazol acts by targeting the H^+/ K^+-ATPase enzyme, the final biological machine—or Proton Pump—in the stomach's acid-secreting cells. The drug is activated by the local acid environment into a metabolite that forms a permanent covalent bond with the enzyme, causing its irreversible inhibition. This molecular action stops the extrusion of hydrogen ions ( H^+), resulting in a sustained reduction of gastric acid output.

Acid-Dependent Activation

The drug is a prodrug that must be converted into its active form in the highly acidic microenvironment of the acid-secreting cell canaliculi. This acid-dependent activation is essential for concentrating the drug's activity to the gastric lining, minimizing systemic generation of the active compound. This specificity concentrates its effect on the final common pathway for acid secretion, independent of the initial physiological trigger.

Sustained Physiological Effect via Enzyme Synthesis

Because the drug's binding to the enzyme is irreversible, the stomach can only recover its full acid-secreting function by synthesizing and inserting new Proton Pumps into the cell membrane. This mechanism dictates that the duration of the physiological effect is determined by the slow rate of cellular protein turnover (approximately 48 to 72 hours), allowing a single dose to maintain an elevated intragastric pH long after the drug has cleared the bloodstream.

Dosage and Administration Information

How to Use Orazol: Official Administration Guidelines

Orazol (Omeprazole) is administered according to standardized protocols, focusing on both the oral and intravenous routes, depending on the clinical context. The medicine's delayed-release formulation is central to its usage instructions, requiring specific intake procedures to ensure the drug's integrity.

Administration Protocol

Instruction Category	Official Guideline
Route of Administration	Primarily Oral (capsules/tablets); Intravenous (IV) Infusion is used as an alternative when oral intake is temporarily inappropriate.
Dosing Schedule	Most regimens use 20 mg or 40 mg once daily. High doses for specific conditions may be individually adjusted, with some patients receiving up to 360 mg daily, which must be given in divided doses.
Timing in Relation to Meals	Must be taken before eating, preferably in the morning.
Duration of Use	Used for defined short-term courses (typically 4 to 8 weeks) or for long-term maintenance in conditions requiring prolonged acid control.

Procedural Administration and Adjustments

Orazol must be swallowed whole with liquid; the delayed-release capsules or tablets must not be crushed, chewed, or split as this compromises the essential enteric coating. For patients with difficulty swallowing, the pellets may be mixed with a small amount of an appropriate slightly acidic liquid or soft food (e.g., applesauce).

Dose adjustments are required for patients with hepatic impairment, where a lower 10 mg to 20 mg once-daily dose may be sufficient. However, for older adults and individuals with renal impairment, a dose modification is typically not required.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Orazol

Evidence for Healing Acid-Related Tissue Damage (Erosive Esophagitis & Ulcers)

The research exploring outcomes related to tissue damage, such as erosive esophagitis (EE) and stomach or duodenal ulcers, relies primarily on Randomized Controlled Trials (RCTs). These short-term studies, typically lasting 4 to 8 weeks, were used in research exploring how endoscopic healing rates are measured, which involves visually confirming tissue repair. Patient outcomes were also observed over longer follow-up periods to track changes in healing status. The research in this area is characterized by a high volume of consistent Randomized Controlled Trials. Studies also examined the maintenance phase, describing patterns related to preserving tissue integrity and preventing the return of erosions or ulcers.

Evidence for Managing Symptomatic Acid Reflux (GERD)

Evidence for Orazol's use in research exploring symptomatic outcomes related to Gastroesophageal Reflux Disease (GERD) stems largely from short-term RCTs that typically evaluated patient outcomes over two to eight weeks. These trials focused on outcomes related to physical discomfort, primarily measuring changes in the frequency and intensity of symptoms like heartburn and acid regurgitation. Research also monitored changes measured during the study period, helping to contextualize how patients reported their experience and daily functioning. Research describes variations in measured response rates between patients with visible tissue damage and those with Non-Erosive Reflux Disease (NERD), where measured response appears to be less predictable.

What Remains Uncertain About the Evidence Base

The research provides context but not individual predictions, and findings describe group patterns, not personal outcomes. Several areas where data are still emerging or where the evidence is limited have been noted by researchers: The full spectrum of long-term effects on physiological markers beyond acid control are not fully established. Follow-up durations in the highest quality trials were typically limited to one year or less, meaning that evidence for multi-year outcomes remains insufficient. Additionally, comparative evidence studying Orazol against all other modern acid suppressants over long periods is not universally available.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Orazol (FAQ)

Q: What is Orazol used for?

A: Orazol is indicated for the short-term treatment of active duodenal ulcer. It is also approved for the maintenance treatment of duodenal ulcers following initial healing. Orazol is also used to treat gastroesophageal reflux disease (GERD), including the healing of erosive esophagitis. Additionally, it may be prescribed for the long-term management of pathological hypersecretory conditions, such as Zollinger-Ellison syndrome.

Q: How does Orazol work in the body?

A: Orazol belongs to a class of medications called proton pump inhibitors (PPIs). Its mechanism involves decreasing the amount of acid produced in the stomach. Specifically, it acts on the proton pumps found in the parietal cells of the stomach lining, which are responsible for the final step in acid secretion. This action helps to reduce acid exposure to the esophagus and stomach lining, which may allow ulcers and erosions to heal.

Q: What are the potential side effects of taking Orazol?

A: As with many medications, Orazol may be associated with side effects. Common reports include headache, diarrhea, abdominal pain, nausea, and flatulence. Less common but more serious considerations, particularly with long-term use, have been noted in research, such as potential changes in vitamin B12 levels or bone density. It is important to discuss any concerns or side effects with a healthcare provider.

Q: Can Orazol be taken with other medications?

A: Orazol has the potential to interact with a number of other medications. This may be due to its effect on stomach acid levels or its metabolism by liver enzymes. Examples of drug classes that may interact include certain antivirals, antifungals, anticoagulants, and methotrexate. Always inform your healthcare professional about all current medications, supplements, and herbal products you are taking to assess for potential interactions.

Q: Is Orazol safe for long-term use?

A: The safety profile of Orazol for long-term use has been studied. While it is generally well-tolerated for short-term courses as prescribed, there are some potential risks associated with prolonged use (typically over one year), including an observed association with conditions like Clostridium difficile-associated diarrhea and potential hypomagnesemia. A healthcare provider will evaluate the necessity of long-term therapy and monitor for potential issues if extended use is required.

Q: What should I do if I miss a scheduled amount of Orazol?

A: If a scheduled amount of Orazol is missed, the general guidance is to take it as soon as you remember. However, if it is nearly time for the next scheduled amount, it is typically recommended to skip the missed amount and resume the regular schedule. It is important not to take two amounts at once to compensate. Consistency in following the prescribed schedule is essential, and any questions about a missed amount should be directed to the prescribing healthcare professional.

How should Orazol be stored and disposed of?

To maintain the effectiveness and safety of Orazol, it must be stored correctly. Keep the medication in the container in which it was dispensed, ensuring the cap is tightly closed. Store Orazol at controlled room temperature, typically between 68 F and 77 F (20 C and 25 C), and protect it from excessive heat, moisture, and light. Avoid storing Orazol in damp locations like a bathroom or near a kitchen stove. Always keep this and all medications out of the reach and sight of children and pets.

Disposal Guidelines

When disposing of expired or unused Orazol, do not flush it down a toilet or pour it down a drain unless specifically instructed to do so by the manufacturer or the U.S. Food and Drug Administration (FDA) flush list. The best method is to use a community drug take-back program. If a take-back program is unavailable, mix the medication with an unappealing substance, such as used coffee grounds or cat litter. Place this mixture in a sealed bag or container and dispose of it in the household trash. Before throwing away the empty container, scratch out all personal information on the prescription label.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Peru

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z